Orforglipron Tablet for Weight Loss Demonstrates Significant Weight Reduction

• Orforglipron helps to lose up to 12% of body weight over 72 weeks.
• The tablet is a more convenient alternative to injection for weight loss.
• A global launch of the drug is planned for the end of the year.

The new weight loss tablet, named orforglipron, could be available as early as next year. This drug, developed by Eli Lilly, demonstrated significant results in clinical trials, where patients lost an average of 12.3 kg over 72 weeks.

Orforglipron works by reducing appetite and increasing feelings of fullness. It is important to note that nearly 10% of participants discontinued the drug due to side effects, such as nausea and diarrhea.

The tablet is an alternative to injectable medications, which, while more effective, may be less convenient for patients. For example, the injectable drug Mounjaro ensures weight loss of up to 22%, but requires regular injections.

In the studied trial, 3,127 adults participated, who suffered from obesity or had weight-related medical issues. As a result, improvements were also observed in levels of cholesterol, fatty acids, and arterial stiffness.

Experts expect that the tablet will be more affordable than injectable medications, thus allowing a greater number of patients to access it. Dr. Kenneth Caster from Eli Lilly noted that the company plans to submit an application for the licensing of orforglipron by the end of the year and is preparing for the global launch of the drug.

In summary, orforglipron is a promising step forward in the treatment of obesity, although its effectiveness is lower compared to injectable agents. Full results of the research will be presented at the upcoming conference of the European Association for the Study of Diabetes in September 2025.

Tags: Well-being/Research